Physicians' Academy for Cardiovascular Education

DPP4 inhibitor is safe in older diabetic participants

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)

Literature - Bethel AM, Engel SS, Green JB, et al. - Diabetes Care 2017; published online ahead of print

Main results

Conclusion

In a large group of participants ≥75 years with well-controlled diabetes, sitagliptin did not increase the risk of serious hypoglycaemia and was neutral with respect to CV outcomes during 3 years of follow-up. These results contribute to better decision making, when it comes to the treatment of older diabetic patients in clinical practice.

References

Show references

Find this article online at Diabetes Care

Share this page with your colleagues and friends: